Healthcare >> CEO Interviews >> May 29, 2000
DR. STANLEY T. CROOKE, MD, PhD is Founder, Chairman and Chief Executive
Officer of Isis Pharmaceuticals. Isis is a development stage
biopharmaceutical company. Dr. Crooke is currently a member of the Board
of Directors of EPIX Medical, Inc., Cambridge, Massachusetts; Idun
Pharmaceuticals, Inc., La Jolla, California; Valentis, Inc. of San
Francisco, California, formed by the merger of GeneMedicine, Inc. and
Megabios; Axon Instruments, Foster City, CA; and Synsorb Biotech, Inc.,
Calgary, Alberta, Canada. He is a former member of the Board of
Directors of SIBIA Neurosciences, the biotechnology industry
organization, Section Editor for biological and immunologicals for
Expert Opinion on Investigational Drugs and a member of the Editorial
Advisory Board of The Journal of Drug Targeting, Gene Therapy and
Molecular Biology and Antisense Research and Development. Prior to
founding Isis, Dr. Crooke was President of Research and Development for
SmithKline Beecham Corporation (SKB). Prior to joining SKB, Dr. Crooke
helped establish the anticancer drug discovery and development program
at Bristol-Myers. In addition to his involvement in the pharmaceutical
industry, Dr. Crooke also maintains active academic positions. He is
currently an Adjunct Professor at the University of California, San
Diego and San Diego State University. Profile
Inc?
Dr. Crooke: Isis is an 11-year-old genomics-based biotechnology company
that since its inception has been focused
